Carbapenem-Resistant Acinetobacter baumannii: Applying Best Practices in Complex Clinical Scenarios

CCO Infectious Disease Podcast

English - November 15, 2023 19:12 - 28 minutes - 26.4 MB
Courses Education Science Life Sciences hiv covid-19 cme hepatitis b hbv id medical education coronavirus hepatitis c hcv Homepage Download Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Where We’re Going: The Next Wave of Antiretroviral Innovations

Next Episode: DTR-Pseudomonas aeruginosa: Applying Best Practices in Complex Clinical Scenarios

In this episode, Emily Heil, PharmD, MS, BCIDP, AAHIVP; Laila Woc-Colburn, MD; and Trevor Van Schooneveld, MD, FSHEA, FACP, discuss their approach to managing infections involving carbapenem-resistant Acinetobacter baumannii (CRAB), including:

Mechanisms for β-lactam resistanceAdditional resistance mechanisms and virulence factors2023 IDSA guidance recommendations for moderate to severe CRAB infectionsThe latest clinical data by antimicrobial therapy/regimen:SulbactamMeropenem and colistinCarbapenem, sulbactam, and polymyxin BTetracyclinesCefiderocolSulbactam/durlobactam and carbapenems

Program Director:

Trevor Van Schooneveld, MD, FSHEA, FACP
Professor, Division of Infectious Diseases
Program Director, Infectious Diseases Fellowship
Medical Director, Antimicrobial Stewardship Program
University of Nebraska Medical Center
Omaha, Nebraska

Faculty:

Emily Heil, PharmD, MS, BCIDP, AAHIVP
Associate Professor
Department of Pharmacy
University of Maryland
School of Pharmacy
ID Clinical Pharmacy Specialist
University of Maryland Medical Center
Baltimore, Maryland

Laila Woc-Colburn, MD
Associate Professor
Division of Infectious Diseases
Emory University School of Medicine
Atlanta, Georgia

Content based on a CME program supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.

Follow along with a downloadable slideset at:
https://bit.ly/476v2wI

Link to full program:
https://bit.ly/40Mmicz